---
layout: default
title: Gefitinib
description: "Gefitinib çš„è€è—¥æ–°ç”¨æ½›åŠ›åˆ†æã€‚æ¨¡å‹é æ¸¬ç­‰ç´š L5ï¼ŒåŒ…å« 10 å€‹é æ¸¬é©æ‡‰ç—‡ã€‚æŸ¥çœ‹ AI é æ¸¬èˆ‡è‡¨åºŠè­‰æ“šå®Œæ•´å ±å‘Šã€‚"
parent: åƒ…æ¨¡å‹é æ¸¬ (L5)
nav_order: 76
evidence_level: L3
indication_count: 10
---

# Gefitinib

<p style="font-size: 1.25rem; color: #666; margin-bottom: 1.5rem;">
è­‰æ“šç­‰ç´š: <strong>L5</strong> | é æ¸¬é©æ‡‰ç—‡: <strong>10</strong> å€‹
</p>

---

<div id="pharmacist">

## è—¥å¸«è©•ä¼°å ±å‘Š

</div>

# Gefitinib (å‰éæ›¿å°¼) - è—¥å¸«è©•ä¼°å ±å‘Š

## ä¸€å¥è©±ç¸½çµ

<p class="key-answer" data-question="Gefitinib å¯ä»¥ç”¨æ–¼æ²»ç™‚ä»€éº¼æ–°é©æ‡‰ç—‡ï¼Ÿ">
å‰éæ›¿å°¼æ˜¯ä¸€ç¨® EGFR é…ªèƒºé…¸æ¿€é…¶æŠ‘åˆ¶åŠ‘ï¼ŒTxGNN é æ¸¬å…¶å°å¤šç¨®çº–ç¶­ç˜¤æ¨£ç—…è®Šå’Œè‚ºéƒ¨è‰¯æ€§è…«ç˜¤æœ‰æ½›åœ¨ç™‚æ•ˆï¼Œé€™äº›é æ¸¬åŸºæ–¼ EGFR è¨Šè™Ÿå‚³å°åœ¨ç´°èƒå¢æ®–ä¸­çš„è§’è‰²ï¼Œä½†ç›®å‰ç¼ºä¹è‡¨åºŠè­‰æ“šæ”¯æŒã€‚
</p>

## å¿«é€Ÿç¸½è¦½

| é …ç›® | å…§å®¹ |
|------|------|
| è—¥ç‰©å­¸å | Gefitinib |
| å°ç£å•†å“å | åŸºæ‰¶èƒ½è†œè¡£éŒ  250 æ¯«å…‹ã€è‰¾ç‘è (IRESSA) |
| DrugBank ID | DB00317 |
| åŸæ ¸å‡†é©æ‡‰ç—‡ | EGFR-TK çªè®Šé™½æ€§éå°ç´°èƒè‚ºç™Œ (NSCLC) |
| é æ¸¬æ–°é©æ‡‰ç—‡ | fibromatosis, gingivalã€fibroma of lungã€inclusion body myopathy with early-onset Paget disease with or without frontotemporal dementiaã€hamartoma of lungã€lung hilum carcinomaã€lung benign neoplasmã€Leukomelanoderma-infantilism-intellectual disability-hypodontia-hypotrichosis syndromeã€lung germ cell tumorã€pulmonary sulcus neoplasmã€junctional epidermolysis bullosa |
| æœ€é«˜è­‰æ“šç­‰ç´š | L4 (å‰è‡¨åºŠ/ç—…ä¾‹å ±å‘Š) |
| å°ç£ä¸Šå¸‚ç‹€æ…‹ | æœ‰æ•ˆè¨±å¯è­‰ |



## é æ¸¬é©æ‡‰ç—‡è©³ç´°åˆ†æ

<details class="indication-section" open>
<summary>
<span class="indication-name">1. fibromatosis, gingival</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.89%</span> <span class="primary-badge">ä¸»è¦åˆ†æ</span>
</summary>
<div class="indication-content">

<h3>ç‚ºä»€éº¼é€™å€‹é æ¸¬åˆç†ï¼Ÿ</h3>

<p>å‰éæ›¿å°¼é€éæŠ‘åˆ¶ EGFR é…ªèƒºé…¸æ¿€é…¶æ´»æ€§ä¾†é˜»æ–·ç´°èƒå¢æ®–è¨Šè™Ÿï¼Œå…¶é æ¸¬é©æ‡‰ç—‡å¯å¾ä»¥ä¸‹è§’åº¦ç†è§£ï¼š</p>

<ol>
<li><strong>ç‰™é½¦çº–ç¶­ç˜¤</strong> (TxGNN Score: 0.999, Rank: 2960)ï¼š</li>
</ol>
<ul>
<li>EGFR è¨Šè™Ÿå‚³å°èˆ‡çº–ç¶­æ¯ç´°èƒå¢æ®–ç›¸é—œ</li>
<li>éƒ¨åˆ†ç‰™é½¦çº–ç¶­ç˜¤å¯èƒ½ç”± EGFR éåº¦æ´»åŒ–é©…å‹•</li>
<li>å€¼å¾—æ³¨æ„çš„æ˜¯ï¼ŒEGFR-TKI æœ¬èº«å¯èƒ½å°è‡´å£è…”é»è†œç‚</li>

</ul>
<ol>
<li><strong>è‚ºçº–ç¶­ç˜¤ / è‚ºéŒ¯æ§‹ç˜¤</strong> (TxGNN Score: 0.999, Ranks: 3554, 3683)ï¼š</li>
</ol>
<ul>
<li>é€™äº›ç‚ºè‚ºéƒ¨è‰¯æ€§è…«ç˜¤</li>
<li>è€ƒé‡åˆ° gefitinib çš„è‚ºéƒ¨çµ„ç¹”åˆ†ä½ˆç‰¹æ€§ï¼Œé æ¸¬æœ‰å…¶åˆç†æ€§</li>
<li>ä½†è‰¯æ€§è…«ç˜¤é€šå¸¸ä¸éœ€ TKI æ²»ç™‚</li>

</ul>
<ol>
<li><strong>é¡é¡³è‘‰å¤±æ™ºä¼´åŒ…æ¶µé«”è‚Œç—…</strong> (TxGNN Score: 0.999, Rank: 3649)ï¼š</li>
</ol>
<ul>
<li>æ­¤é æ¸¬è¼ƒé›£è§£é‡‹</li>
<li>å¯èƒ½èˆ‡ç¥ç¶“ä¿è­·ä½œç”¨ç›¸é—œçš„æ¢ç´¢æ€§ç ”ç©¶æœ‰é—œ</li>
</ul>

<h3>è‡¨åºŠè©¦é©—</h3>

<p>é‡å°é æ¸¬çš„æ–°é©æ‡‰ç—‡ï¼Œ<strong>æœªæª¢ç´¢åˆ°ç›´æ¥ç›¸é—œçš„è‡¨åºŠè©¦é©—</strong>ã€‚</p>

<p>ä½†å­˜åœ¨å¤§é‡ gefitinib ç”¨æ–¼åŸæ ¸å‡†é©æ‡‰ç—‡ï¼ˆNSCLCï¼‰çš„è‡¨åºŠè©¦é©—ã€‚</p>

<p><strong>è­‰æ“šç­‰ç´šï¼šL5</strong> - é æ¸¬é©æ‡‰ç—‡åƒ…æœ‰ç†è«–æ©Ÿè½‰æ”¯æŒï¼Œç„¡è‡¨åºŠè­‰æ“šã€‚</p>

<h3>ç›¸é—œæ–‡ç»</h3>

<p>### é¡é¡³è‘‰å¤±æ™ºç›¸é—œï¼ˆ20 ç¯‡æ–‡ç»ï¼‰</p>

<p>æ–‡ç»æª¢ç´¢çµæœå¤šç‚ºé¡é¡³è‘‰å¤±æ™ºçš„ä¸€èˆ¬æ€§ç¶œè¿°æ–‡ç« ï¼Œè€Œé gefitinib æ²»ç™‚è©²ç–¾ç—…çš„ç ”ç©¶ï¼š</p>

<ol>
<li><strong>Bang J et al. (2015)</strong> - Lancet</li>
</ol>
<ul>
<li>é¡é¡³è‘‰å¤±æ™ºç¶œè¿°</li>
<li>è¨è«–è¨ºæ–·å’Œæ²»ç™‚é€²å±•ï¼Œä½†æœªæ¶‰åŠ EGFR-TKI</li>

</ul>
<ol>
<li><strong>Boeve BF et al. (2022)</strong> - Lancet Neurology</li>
</ol>
<ul>
<li>é¡é¡³è‘‰å¤±æ™ºè¨ºæ–·å’Œç”Ÿç‰©æ¨™è¨˜é€²å±•</li>
<li>æåŠåˆ†å­æ¨™é¶æ²»ç™‚ç ”ç©¶æ–¹å‘</li>

</ul>
<p><strong>æ³¨æ„ï¼š</strong> é€™äº›æ–‡ç»çš„é—œè¯æ€§è¼ƒä½ï¼Œåæ˜ çš„æ˜¯çŸ¥è­˜åœ–è­œä¸­ç–¾ç—…çš„é€£çµè€Œéç›´æ¥çš„æ²»ç™‚è­‰æ“šã€‚</p>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">2. fibroma of lung</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.86%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">3. inclusion body myopathy with early-onset Paget disease with or without frontotemporal dementia</span>
<span class="evidence-badge evidence-L4">L4</span>
<span class="prediction-score">99.86%</span>
</summary>
<div class="indication-content">

<h3>ç›¸é—œæ–‡ç»ï¼ˆ20 ç¯‡ï¼‰</h3>

<table>
<thead>
<tr><th>PMID</th><th>å¹´ä»½</th><th>é¡å‹</th><th>æœŸåˆŠ</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/26595641/" target="_blank">26595641</a></td><td>2015</td><td>Article</td><td>Lancet (London, Engl</td><td>Frontotemporal dementia.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/28410663/" target="_blank">28410663</a></td><td>2017</td><td>Article</td><td>Neurologic clinics</td><td>Frontotemporal Dementia.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/35182511/" target="_blank">35182511</a></td><td>2022</td><td>Article</td><td>The Lancet. Neurolog</td><td>Advances and controversies in frontotemporal dementia: diagn...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/21810890/" target="_blank">21810890</a></td><td>2011</td><td>Article</td><td>Brain : a journal of</td><td>Sensitivity of revised diagnostic criteria for the behaviour...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/35678399/" target="_blank">35678399</a></td><td>2022</td><td>Article</td><td>Continuum (Minneapol</td><td>Behavioral Variant Frontotemporal Dementia.</td></tr>
</tbody>
</table>
<p><em>...åŠå…¶ä»– 15 ç¯‡æ–‡ç»</em></p>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">4. hamartoma of lung</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.86%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">5. lung hilum carcinoma</span>
<span class="evidence-badge evidence-L4">L4</span>
<span class="prediction-score">99.86%</span>
</summary>
<div class="indication-content">

<h3>ç›¸é—œæ–‡ç»ï¼ˆ1 ç¯‡ï¼‰</h3>

<table>
<thead>
<tr><th>PMID</th><th>å¹´ä»½</th><th>é¡å‹</th><th>æœŸåˆŠ</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/22688581/" target="_blank">22688581</a></td><td>2012</td><td>Article</td><td>General thoracic and</td><td>Salvage surgery for a super-responder by gefitinib therapy f...</td></tr>
</tbody>
</table>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">6. lung benign neoplasm</span>
<span class="evidence-badge evidence-L4">L4</span>
<span class="prediction-score">99.85%</span>
</summary>
<div class="indication-content">

<h3>ç›¸é—œæ–‡ç»ï¼ˆ20 ç¯‡ï¼‰</h3>

<table>
<thead>
<tr><th>PMID</th><th>å¹´ä»½</th><th>é¡å‹</th><th>æœŸåˆŠ</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/32778129/" target="_blank">32778129</a></td><td>2020</td><td>Article</td><td>Respiratory research</td><td>FGL1 regulates acquired resistance to Gefitinib by inhibitin...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/24794908/" target="_blank">24794908</a></td><td>2014</td><td>Article</td><td>Profiles of drug sub</td><td>Gefitinib.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/37057810/" target="_blank">37057810</a></td><td>2023</td><td>Article</td><td>The Kaohsiung journa</td><td>Dihydroartemisinin enhances gefitinib cytotoxicity against l...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/23140355/" target="_blank">23140355</a></td><td>2014</td><td>Article</td><td>Anti-cancer agents i</td><td>Erlotinib and gefitinib for elderly patients with advanced n...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/38967523/" target="_blank">38967523</a></td><td>2024</td><td>Article</td><td>Cancer medicine</td><td>METTL1/FOXM1 promotes lung adenocarcinoma progression and ge...</td></tr>
</tbody>
</table>
<p><em>...åŠå…¶ä»– 15 ç¯‡æ–‡ç»</em></p>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">7. Leukomelanoderma-infantilism-intellectual disability-hypodontia-hypotrichosis syndrome</span>
<span class="evidence-badge evidence-L4">L4</span>
<span class="prediction-score">99.84%</span>
</summary>
<div class="indication-content">

<h3>ç›¸é—œæ–‡ç»ï¼ˆ20 ç¯‡ï¼‰</h3>

<table>
<thead>
<tr><th>PMID</th><th>å¹´ä»½</th><th>é¡å‹</th><th>æœŸåˆŠ</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/38288441/" target="_blank">38288441</a></td><td>2024</td><td>Article</td><td>Frontiers in pharmac</td><td>Valsartan attenuates LPS-induced ALI by modulating NF-ÎºB and...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/39281285/" target="_blank">39281285</a></td><td>2024</td><td>Article</td><td>Frontiers in pharmac</td><td>Gastrointestinal tract organoids as novel tools in drug disc...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/30033041/" target="_blank">30033041</a></td><td>2019</td><td>Article</td><td>The lancet. Diabetes</td><td>Advances in the medical treatment of Cushing&#x27;s syndrome.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/18931563/" target="_blank">18931563</a></td><td>2008</td><td>Article</td><td>Gan to kagaku ryoho.</td><td>[Cutaneous toxicities].</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/34474028/" target="_blank">34474028</a></td><td>2021</td><td>Article</td><td>European journal of </td><td>Mechanisms of gefitinib-induced QT prolongation.</td></tr>
</tbody>
</table>
<p><em>...åŠå…¶ä»– 15 ç¯‡æ–‡ç»</em></p>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">8. lung germ cell tumor</span>
<span class="evidence-badge evidence-L3">L3</span>
<span class="prediction-score">99.84%</span>
</summary>
<div class="indication-content">

<h3>è‡¨åºŠè©¦é©—ï¼ˆ1 é …ï¼‰</h3>

<table>
<thead>
<tr><th>è©¦é©—ç·¨è™Ÿ</th><th>éšæ®µ</th><th>ç‹€æ…‹</th><th>äººæ•¸</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00068497" target="_blank">NCT00068497</a></td><td>NA</td><td>COMPLETED</td><td>40</td><td>Single Agent ZD-1839 (NSC-715055, IND-61187) in Patients With Advanced Head and ...</td></tr>
</tbody>
</table>

<h3>ç›¸é—œæ–‡ç»ï¼ˆ20 ç¯‡ï¼‰</h3>

<table>
<thead>
<tr><th>PMID</th><th>å¹´ä»½</th><th>é¡å‹</th><th>æœŸåˆŠ</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/22588876/" target="_blank">22588876</a></td><td>2012</td><td>Article</td><td>Cancer discovery</td><td>Occupy EGFR.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/21485758/" target="_blank">21485758</a></td><td>2011</td><td>Article</td><td>Acta clinica Belgica</td><td>Epidermal growth factor receptor targeted therapies for soli...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/38261467/" target="_blank">38261467</a></td><td>2024</td><td>Article</td><td>Clinical cancer rese</td><td>Germline USP36 Mutation Confers Resistance to EGFR-TKIs by U...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/16330971/" target="_blank">16330971</a></td><td>2005</td><td>Article</td><td>Cancer nursing</td><td>Gefitinib (Iressa, ZD1839) and tyrosine kinase inhibitors: t...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/24618893/" target="_blank">24618893</a></td><td>2014</td><td>Article</td><td>Cancer biology &amp; the</td><td>Met in lung cancer.</td></tr>
</tbody>
</table>
<p><em>...åŠå…¶ä»– 15 ç¯‡æ–‡ç»</em></p>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">9. pulmonary sulcus neoplasm</span>
<span class="evidence-badge evidence-L4">L4</span>
<span class="prediction-score">99.84%</span>
</summary>
<div class="indication-content">

<h3>ç›¸é—œæ–‡ç»ï¼ˆ2 ç¯‡ï¼‰</h3>

<table>
<thead>
<tr><th>PMID</th><th>å¹´ä»½</th><th>é¡å‹</th><th>æœŸåˆŠ</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/16015545/" target="_blank">16015545</a></td><td>2005</td><td>Article</td><td>Seminars in oncology</td><td>An overview of Eastern Cooperative Oncology Group stage III ...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/21441747/" target="_blank">21441747</a></td><td>2011</td><td>Article</td><td>Neurologia medico-ch</td><td>Focal leptomeningeal metastasis following curative surgery f...</td></tr>
</tbody>
</table>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">10. junctional epidermolysis bullosa</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.84%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>


## å°ç£ä¸Šå¸‚è³‡è¨Š

**æœ‰æ•ˆè¨±å¯è­‰ï¼š**

| è¨±å¯è­‰å­—è™Ÿ | å•†å“å | è¨±å¯è­‰æŒæœ‰è€… |
|------------|--------|--------------|
| è¡›ç½²è—¥è¼¸å­—ç¬¬024308è™Ÿ | è‰¾ç‘èè†œè¡£éŒ  250 æ¯«å…‹ | å°ç£é˜¿æ–¯ä¹™åˆ©åº· |
| è¡›éƒ¨è—¥è£½å­—ç¬¬059XXXè™Ÿ | åŸºæ‰¶èƒ½è†œè¡£éŒ  250 æ¯«å…‹ | å¤šå®¶å­¸åè—¥å»  |

**æ ¸å‡†é©æ‡‰ç—‡ï¼š**
- å…·æœ‰ EGFR-TK çªè®Šä¹‹å±€éƒ¨ä¾µçŠ¯æ€§æˆ–è½‰ç§»æ€§éå°ç´°èƒè‚ºç™Œ (NSCLC) ç—…æ‚£ä¹‹ç¬¬ä¸€ç·šæ²»ç™‚
- å…ˆå‰å·²æ¥å—åŒ–å­¸æ²»ç™‚å¾Œä»å±€éƒ¨æƒ¡åŒ–æˆ–è½‰ç§»ä¹‹è‚ºè…ºç™Œç—…æ‚£ä¹‹ç¬¬äºŒç·šç”¨è—¥

## å®‰å…¨æ€§è€ƒé‡

### é»‘æ¡†è­¦èª
- **é–“è³ªæ€§è‚ºç—… (ILD)**ï¼šå¯èƒ½ç™¼ç”Ÿè‡´å‘½æ€§é–“è³ªæ€§è‚ºç—…ï¼Œç™¼ç”Ÿç‡ç´„ 1-3%
- å‡ºç¾å‘¼å¸å›°é›£ã€å’³å—½æˆ–ç™¼ç‡’æ™‚æ‡‰ç«‹å³åœè—¥ä¸¦è©•ä¼°

### å¸¸è¦‹ä¸è‰¯åæ‡‰

| ä¸è‰¯åæ‡‰ | ç™¼ç”Ÿç‡ |
|----------|--------|
| çš®ç–¹ | 40-50% |
| è…¹ç€‰ | 30-40% |
| çš®è†šä¹¾ç‡¥ | 20-30% |
| å™å¿ƒ | 15-25% |
| ç”²æºç‚ | 10-20% |

### è—¥ç‰©äº¤äº’ä½œç”¨

| äº¤äº’ä½œç”¨è—¥ç‰© | åš´é‡ç¨‹åº¦ | èªªæ˜ |
|--------------|----------|------|
| CYP3A4 èª˜å°åŠ‘ | Major | Rifampicin ç­‰å¯é™ä½ gefitinib æ¿ƒåº¦ |
| CYP3A4 æŠ‘åˆ¶åŠ‘ | Moderate | Ketoconazole ç­‰å¯å¢åŠ  gefitinib æ¿ƒåº¦ |
| Warfarin | Moderate | å¯èƒ½å¢åŠ å‡ºè¡€é¢¨éšª |
| PPI/H2 blocker | Moderate | å¯èƒ½é™ä½ gefitinib å¸æ”¶ |

### ç‰¹æ®Šæ—ç¾¤
- **è‚åŠŸèƒ½ä¸å…¨**ï¼šä¸­é‡åº¦è‚åŠŸèƒ½ä¸å…¨æ‚£è€…éœ€è¬¹æ…ä½¿ç”¨
- **å­•å©¦**ï¼šç¦ç”¨ï¼Œç‚º FDA æ‡·å­•åˆ†é¡ D ç´š

### è—¥ç‰©-é£Ÿç‰©äº¤äº’ä½œç”¨ (DFI)

**è‘¡è„æŸš** ğŸ”´ Major
- å½±éŸ¿ï¼šè‘¡è„æŸšé¡¯è‘—å¢åŠ  Gefitinib è¡€ä¸­æ¿ƒåº¦å’Œæ¯’æ€§
- å»ºè­°ï¼šé¿å…è‘¡è„æŸš

### è—¥ç‰©-è‰è—¥äº¤äº’ä½œç”¨ (DHI)

**è–ç´„ç¿°è‰ï¼ˆè²«è‘‰é€£ç¿¹ï¼‰** ğŸ”´ Major
- å½±éŸ¿ï¼šè–ç´„ç¿°è‰é¡¯è‘—é™ä½ Gefitinib è¡€ä¸­æ¿ƒåº¦
- å»ºè­°ï¼šç¦æ­¢ä½µç”¨


### è—¥ç‰©-ç–¾ç—…æ³¨æ„äº‹é … (DDSI)

<div class="ddsi-source">è³‡æ–™ä¾†æºï¼š<a href="https://ddinter2.scbdd.com/" target="_blank">DDInter 2.0</a>ï¼ˆåŸæ–‡å…§å®¹è«‹åƒé–±è©²ç¶²ç«™ï¼‰</div>

**è…è‡Ÿç–¾ç—…** ğŸŸ¡ Moderate
- å¯èƒ½æœ‰åš´é‡ä¸è‰¯åæ‡‰ã€‚

**Stevens-Johnson Syndrome** ğŸŸ¢ Minor
- éœ€å®šæœŸç›£æ¸¬ã€‚å¯èƒ½å±åŠç”Ÿå‘½ã€‚å¿…è¦æ™‚æ‡‰åœæ­¢æ²»ç™‚ã€‚

**Gastrointestinal Diseases** ğŸŸ¢ Minor
- å¯èƒ½æœ‰è‡´å‘½é¢¨éšªã€‚å¿…è¦æ™‚æ‡‰åœæ­¢æ²»ç™‚ã€‚

**Eye Diseases** ğŸŸ¢ Minor
- å¿…è¦æ™‚æ‡‰åœæ­¢æ²»ç™‚ã€‚

**Lung Diseases** ğŸŸ¢ Minor
- æ‡‰è¬¹æ…ä½¿ç”¨æœ¬è—¥ç‰©ã€‚å¯èƒ½æœ‰è‡´å‘½é¢¨éšªã€‚å‡ºç¾ç—‡ç‹€æ™‚æ‡‰è€ƒæ…®åœè—¥ã€‚

**è‚è‡Ÿç–¾ç—…** ğŸŸ¢ Minor
- éœ€å®šæœŸç›£æ¸¬ã€‚å¯èƒ½æœ‰åš´é‡ä¸è‰¯åæ‡‰ã€‚å¿…è¦æ™‚æ‡‰åœæ­¢æ²»ç™‚ã€‚

## çµè«–èˆ‡ä¸‹ä¸€æ­¥

### é æ¸¬è©•ä¼°çµè«–

Gefitinib çš„é æ¸¬æ–°é©æ‡‰ç—‡ï¼ˆçº–ç¶­ç˜¤æ¨£ç—…è®Šã€è‰¯æ€§è‚ºè…«ç˜¤ã€ç¥ç¶“é€€åŒ–æ€§ç–¾ç—…ï¼‰ç›®å‰**ç¼ºä¹è‡¨åºŠè­‰æ“šæ”¯æŒ**ã€‚é›–ç„¶ EGFR è¨Šè™Ÿå‚³å°åœ¨ç´°èƒå¢æ®–ä¸­æ‰®æ¼”é‡è¦è§’è‰²ï¼Œä½†ï¼š

1. è‰¯æ€§è…«ç˜¤é€šå¸¸ä¸éœ€è¦ä½¿ç”¨å…·æœ‰é¡¯è‘—æ¯’æ€§çš„ TKI
2. ç¥ç¶“é€€åŒ–æ€§ç–¾ç—…çš„é æ¸¬ç¼ºä¹æ˜ç¢ºæ©Ÿè½‰åŸºç¤
3. ç¾æœ‰è­‰æ“šç­‰ç´šåƒ…åœç•™åœ¨ç†è«–æ¨æ¸¬

### è­‰æ“šç­‰ç´šç¸½çµ

| é æ¸¬é©æ‡‰ç—‡ | TxGNN Score | è­‰æ“šç­‰ç´š | è©•ä¼° |
|------------|-------------|----------|------|
| ç‰™é½¦çº–ç¶­ç˜¤ | 0.999 | L5 | åƒ…æ©Ÿè½‰æ¨æ¸¬ |
| è‚ºçº–ç¶­ç˜¤ | 0.999 | L5 | åƒ…æ©Ÿè½‰æ¨æ¸¬ |
| é¡é¡³è‘‰å¤±æ™ºä¼´è‚Œç—… | 0.999 | L5 | é—œè¯æ€§ä¸æ˜ |
| è‚ºéŒ¯æ§‹ç˜¤ | 0.999 | L5 | åƒ…æ©Ÿè½‰æ¨æ¸¬ |
| è‚ºé–€ç™Œ | 0.999 | L4 | æœ‰ç—…ä¾‹å ±å‘Šï¼ˆèˆ‡åŸé©æ‡‰ç—‡ç›¸è¿‘ï¼‰|

### å»ºè­°

1. **ä¸å»ºè­°å„ªå…ˆé–‹ç™¼é æ¸¬é©æ‡‰ç—‡**ï¼š
   - ç¼ºä¹è‡¨åºŠå‰è­‰æ“š
   - è—¥ç‰©æ¯’æ€§èˆ‡è‰¯æ€§ç–¾ç—…ä¸åŒ¹é…
   - ç¥ç¶“é€€åŒ–æ€§ç–¾ç—…é æ¸¬æ©Ÿè½‰ä¸æ˜

2. **å¯èƒ½çš„ç ”ç©¶æ–¹å‘**ï¼š
   - è‹¥æœ‰æ–°çš„æ©Ÿè½‰è­‰æ“šæ”¯æŒ EGFR åœ¨çº–ç¶­åŒ–ç–¾ç—…ä¸­çš„è§’è‰²ï¼Œå¯è€ƒæ…®å‰è‡¨åºŠç ”ç©¶
   - é¡é¡³è‘‰å¤±æ™ºèˆ‡åŒ…æ¶µé«”è‚Œç—…çš„é æ¸¬éœ€æ›´å¤šåŸºç¤ç ”ç©¶æ”¯æŒ

3. **ç¾æœ‰é©æ‡‰ç—‡å„ªåŒ–**ï¼š
   - æŒçºŒå„ªåŒ– NSCLC æ²»ç™‚æ–¹æ¡ˆ
   - æ¢ç´¢èˆ‡å…¶ä»– TKI æˆ–å…ç–«ç™‚æ³•çš„çµ„åˆç­–ç•¥

---

*å ±å‘Šç”Ÿæˆæ—¥æœŸï¼š2026-02-11*
*è³‡æ–™ä¾†æºï¼šTxGNN çŸ¥è­˜åœ–è­œé æ¸¬ã€ClinicalTrials.govã€PubMedã€å°ç£ FDA*

---

## ç›¸é—œè—¥ç‰©å ±å‘Š

- [Raloxifene]({{ "/drugs/raloxifene/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Berberine]({{ "/drugs/berberine/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Tenofovir Alafenamide]({{ "/drugs/tenofovir_alafenamide/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Cerliponase Alfa]({{ "/drugs/cerliponase_alfa/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Pemetrexed]({{ "/drugs/pemetrexed/" | relative_url }}) - è­‰æ“šç­‰ç´š L5

---

{% include ai-analysis.html %}

{% include social-share.html %}

## å¼•ç”¨æœ¬å ±å‘Š

å¦‚éœ€å¼•ç”¨æœ¬å ±å‘Šï¼Œè«‹ä½¿ç”¨ä»¥ä¸‹æ ¼å¼ï¼š

**APA æ ¼å¼ï¼š**
```
TwTxGNN. (2026). Gefitinibè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š. https://twtxgnn.yao.care/drugs/gefitinib/
```

**BibTeX æ ¼å¼ï¼š**
```bibtex
@misc{twtxgnn_gefitinib,
  title = {Gefitinibè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š},
  author = {TwTxGNN Team},
  year = {2026},
  url = {https://twtxgnn.yao.care/drugs/gefitinib/}
}
```

---

<div class="disclaimer">
<strong>å…è²¬è²æ˜</strong><br>
æœ¬å ±å‘Šåƒ…ä¾›å­¸è¡“ç ”ç©¶åƒè€ƒï¼Œ<strong>ä¸æ§‹æˆé†«ç™‚å»ºè­°</strong>ã€‚è—¥ç‰©ä½¿ç”¨è«‹éµå¾ªé†«å¸«æŒ‡ç¤ºï¼Œåˆ‡å‹¿è‡ªè¡Œèª¿æ•´ç”¨è—¥ã€‚ä»»ä½•è€è—¥æ–°ç”¨æ±ºç­–éœ€ç¶“éå®Œæ•´çš„è‡¨åºŠé©—è­‰èˆ‡æ³•è¦å¯©æŸ¥ã€‚
<br><br>
<small>æœ€å¾Œå¯©æ ¸ï¼š2026-02-20 | å¯©æ ¸è€…ï¼šTwTxGNN Research Team</small>
</div>

{% include giscus.html %}
